Marlies Wagner1, Michael Helfrich2, Steffen Volz3, Jörg Magerkurth2, Stella Blasel2, Luciana Porto2, Oliver C Singer4, Ralf Deichmann3, Alina Jurcoane2, Elke Hattingen2. 1. Institute of Neuroradiology, University Hospital, Goethe-University, Schleusenweg 2-16, D-60528, Frankfurt am Main, Frankfurt, Germany. marlies.wagner@kgu.de. 2. Institute of Neuroradiology, University Hospital, Goethe-University, Schleusenweg 2-16, D-60528, Frankfurt am Main, Frankfurt, Germany. 3. Brain Imaging Center, University Hospital, Goethe-University, Frankfurt, Germany. 4. Department of Neurology, University Hospital, Goethe-University, Frankfurt, Germany.
Abstract
INTRODUCTION: Quantitative MRI with T2, T2*, and T2' mapping has been shown to non-invasively depict microstructural changes (T2) and oxygenation status (T2* and T2') that are invisible on conventional MRI. Therefore, we aimed to assess whether T2 and T2' quantification detects cerebral (micro-)structural damage and chronic hypoxia in lesions and in normal appearing white matter (WM) and gray matter (GM) of patients with ischemic leukoaraiosis (IL). Measurements were complemented by the assessment of the cerebral blood flow (CBF) and the degree of GM and WM atrophy. METHODS: Eighteen patients with IL and 18 age-matched healthy controls were included. High-resolution, motion-corrected T2, T2*, and T2' mapping, CBF mapping (pulsed arterial spin labeling, PASL), and segmentation of GM and WM were used to depict specific changes in both groups. All parameters were compared between patients and healthy controls, using t testing. Values of p < 0.05 were accepted as statistically significant. RESULTS: Patients showed significantly increased T2 in lesions (p < 0.01) and in unaffected WM (p = 0.045) as well as significantly increased T2* in lesions (p = 0.003). A significant decrease of T2' was detected in patients in unaffected WM (p = 0.027), while no T2' changes were observed in GM (p = 0.13). Both unaffected WM and GM were significantly decreased in volume in the patient-group (p < 0.01). No differences of PASL-based CBF could be shown. CONCLUSION: Non-invasive quantitative MRI with T2, T2*, and T2' mapping might be used to detect subtle structural and metabolic changes in IL. Assessing the grade of microstructural damage and hypoxia might be helpful to monitor disease progression and to perform risk assessment.
INTRODUCTION: Quantitative MRI with T2, T2*, and T2' mapping has been shown to non-invasively depict microstructural changes (T2) and oxygenation status (T2* and T2') that are invisible on conventional MRI. Therefore, we aimed to assess whether T2 and T2' quantification detects cerebral (micro-)structural damage and chronic hypoxia in lesions and in normal appearing white matter (WM) and gray matter (GM) of patients with ischemic leukoaraiosis (IL). Measurements were complemented by the assessment of the cerebral blood flow (CBF) and the degree of GM and WM atrophy. METHODS: Eighteen patients with IL and 18 age-matched healthy controls were included. High-resolution, motion-corrected T2, T2*, and T2' mapping, CBF mapping (pulsed arterial spin labeling, PASL), and segmentation of GM and WM were used to depict specific changes in both groups. All parameters were compared between patients and healthy controls, using t testing. Values of p < 0.05 were accepted as statistically significant. RESULTS:Patients showed significantly increased T2 in lesions (p < 0.01) and in unaffected WM (p = 0.045) as well as significantly increased T2* in lesions (p = 0.003). A significant decrease of T2' was detected in patients in unaffected WM (p = 0.027), while no T2' changes were observed in GM (p = 0.13). Both unaffected WM and GM were significantly decreased in volume in the patient-group (p < 0.01). No differences of PASL-based CBF could be shown. CONCLUSION: Non-invasive quantitative MRI with T2, T2*, and T2' mapping might be used to detect subtle structural and metabolic changes in IL. Assessing the grade of microstructural damage and hypoxia might be helpful to monitor disease progression and to perform risk assessment.
Authors: K Meguro; J Hatazawa; T Yamaguchi; M Itoh; T Matsuzawa; S Ono; H Miyazawa; T Hishinuma; K Yanai; Y Sekita Journal: Ann Neurol Date: 1990-09 Impact factor: 10.422
Authors: Jeff H Duyn; Peter van Gelderen; Tie-Qiang Li; Jacco A de Zwart; Alan P Koretsky; Masaki Fukunaga Journal: Proc Natl Acad Sci U S A Date: 2007-06-22 Impact factor: 11.205
Authors: M O'Sullivan; D J Lythgoe; A C Pereira; P E Summers; J M Jarosz; S C R Williams; H S Markus Journal: Neurology Date: 2002-08-13 Impact factor: 9.910
Authors: Robert J Dawe; Lei Yu; Sue E Leurgans; Julie A Schneider; Aron S Buchman; Konstantinos Arfanakis; David A Bennett; Patricia A Boyle Journal: Neurobiol Aging Date: 2016-06-06 Impact factor: 4.673
Authors: Yulu Shi; Michael J Thrippleton; Stephen D Makin; Ian Marshall; Mirjam I Geerlings; Anton J M de Craen; Mark A van Buchem; Joanna M Wardlaw Journal: J Cereb Blood Flow Metab Date: 2016-08-05 Impact factor: 6.200
Authors: A Seiler; R Deichmann; U Nöth; A Lauer; W Pfeilschifter; O C Singer; M Wagner Journal: AJNR Am J Neuroradiol Date: 2018-05-10 Impact factor: 3.825
Authors: Mark R Etherton; Ona Wu; Pedro Cougo; Anne-Katrin Giese; Lisa Cloonan; Kaitlin M Fitzpatrick; Allison S Kanakis; Gregoire Boulouis; Hasan H Karadeli; Arne Lauer; Jonathan Rosand; Karen L Furie; Natalia S Rost Journal: Neurology Date: 2017-04-05 Impact factor: 9.910
Authors: Sarah Atwi; Arron W S Metcalfe; Andrew D Robertson; Jeremy Rezmovitz; Nicole D Anderson; Bradley J MacIntosh Journal: Front Neurosci Date: 2018-10-18 Impact factor: 4.677
Authors: Alexander Seiler; Ralf Deichmann; Waltraud Pfeilschifter; Elke Hattingen; Oliver C Singer; Marlies Wagner Journal: PLoS One Date: 2016-08-25 Impact factor: 3.240